医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
1期
42-43
,共2页
左绍远%钱金栿%方淑环%张翠香
左紹遠%錢金栿%方淑環%張翠香
좌소원%전금복%방숙배%장취향
红花蜂花粉多糖(PBPC)%S180荷瘤小鼠%抗肿瘤%肿瘤坏死因子-α
紅花蜂花粉多糖(PBPC)%S180荷瘤小鼠%抗腫瘤%腫瘤壞死因子-α
홍화봉화분다당(PBPC)%S180하류소서%항종류%종류배사인자-α
polysaccharide from bee pollen of carthamus tinctorius (PBPC)%S180 - bearing mice%anti-tumor TNF-α
目的：观察红花蜂花粉多糖(PBPC)对荷S180肉瘤小鼠的肿瘤抑制作用。方法：通过建立小鼠S180肉瘤模型，观察PBPC的体内抗肿瘤活性及对小鼠免疫器官的影响，用ELISA法测定荷瘤小鼠血清中肿瘤坏死因子α（TNF-α）的含量。结果：以50，100，150 mg?kg-1剂量的PBPC灌胃给药，连续14d,能明显抑制小鼠S180肉瘤生长，抑制率分别为36.99%、41.78%与49.32%。PBPC对小鼠的免疫器官具有保护作用，PBPC100，150 m g?k g-1的剂量能明显增加荷瘤小鼠的胸腺和脾腺指数。另外，PBPC 50，100，150 mg?kg-1剂量组均能使荷瘤小鼠血清TNF-α显著升高，TNF-α含量分别为314.62，357.34与363.42 pg.L-1。结论：PBPC能明显抑制小鼠S180肉瘤的生长，增加荷瘤小鼠的胸腺和脾腺指数及血清TNF-α含量。提示PBPC促进荷瘤小鼠血清TNF-α的分泌从而引起肿瘤的坏死，可能是其抗肿瘤作用的途径之一。
目的：觀察紅花蜂花粉多糖(PBPC)對荷S180肉瘤小鼠的腫瘤抑製作用。方法：通過建立小鼠S180肉瘤模型，觀察PBPC的體內抗腫瘤活性及對小鼠免疫器官的影響，用ELISA法測定荷瘤小鼠血清中腫瘤壞死因子α（TNF-α）的含量。結果：以50，100，150 mg?kg-1劑量的PBPC灌胃給藥，連續14d,能明顯抑製小鼠S180肉瘤生長，抑製率分彆為36.99%、41.78%與49.32%。PBPC對小鼠的免疫器官具有保護作用，PBPC100，150 m g?k g-1的劑量能明顯增加荷瘤小鼠的胸腺和脾腺指數。另外，PBPC 50，100，150 mg?kg-1劑量組均能使荷瘤小鼠血清TNF-α顯著升高，TNF-α含量分彆為314.62，357.34與363.42 pg.L-1。結論：PBPC能明顯抑製小鼠S180肉瘤的生長，增加荷瘤小鼠的胸腺和脾腺指數及血清TNF-α含量。提示PBPC促進荷瘤小鼠血清TNF-α的分泌從而引起腫瘤的壞死，可能是其抗腫瘤作用的途徑之一。
목적：관찰홍화봉화분다당(PBPC)대하S180육류소서적종류억제작용。방법：통과건립소서S180육류모형，관찰PBPC적체내항종류활성급대소서면역기관적영향，용ELISA법측정하류소서혈청중종류배사인자α（TNF-α）적함량。결과：이50，100，150 mg?kg-1제량적PBPC관위급약，련속14d,능명현억제소서S180육류생장，억제솔분별위36.99%、41.78%여49.32%。PBPC대소서적면역기관구유보호작용，PBPC100，150 m g?k g-1적제량능명현증가하류소서적흉선화비선지수。령외，PBPC 50，100，150 mg?kg-1제량조균능사하류소서혈청TNF-α현저승고，TNF-α함량분별위314.62，357.34여363.42 pg.L-1。결론：PBPC능명현억제소서S180육류적생장，증가하류소서적흉선화비선지수급혈청TNF-α함량。제시PBPC촉진하류소서혈청TNF-α적분비종이인기종류적배사，가능시기항종류작용적도경지일。
Objectives: To observe the anti-tumor activity of of polysaccharide from bee pol en of carthamus tinctorius(PBPC). Methods: The model of S180-bearing mice was established to study the anti-tumor activity and effect on immune organs of PBPC in vivo. Then the serum content of TNF-α was tested by ELISA method Results: With the dosages of 50, 100, 150 mg-kg-1 by ig administration for 14 days, PBPC could significantly inhibit the tumor growth, the inhibition rates were 36.99%、41.78% and 49.32% respectively. On the other hand, compared with the model control group, PBPC 50, 100, 150 mg-kg-1 dosages could markedly increase serum TNF-α in tumor-bearing mice, the concentration of TNF-α were 314.62,357.34 and 363.42 pg.L-1 respectively. In addition, PBPC could increased the thymus and spleen index. Conclusion: PBPC can significantly inhibit the tumor growth in S180-bearing mice, increase the serum TNF-α level. The effect of PBPCⅡ promotes secretion of TNF-α to enhance tumor necrosis may be one of the pathways for PBPC’s effect of anti-tumor.
